Moludi Jalal, Qaisar Shaimaa A, Kadhim Mustafa M, Ahmadi Yasin, Davari Mina
School of Nutritional Sciences and Food Technology, Kermanshah University of Medical Sciences, Kermanshah, 5166614711, Iran.
Behavioral Disease Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Nutr Metab (Lond). 2022 Jul 23;19(1):49. doi: 10.1186/s12986-022-00684-2.
Taurine supplementation as a sulfur-containing amino acid may attenuate and/or alleviate diabetes-induced complications and endothelial dysfunction via its anti-inflammatory and antioxidant activities. Our purpose was to investigate the effect of Taurine supplementation on endothelial dysfunction markers, oxidative stress, inflammation, and glycemic control in patients with type 2 diabetes mellitus (T2DM).
In the current clinical trial, 120 patients with T2DM were randomly allocated to take either Taurine (containing 1 g Taurine, n = 60) or placebo (n = 60) three times per day for an eight-week period. Moreover, all patients were on a low-calorie diet. The primary outcome was fasting blood glucose (FBG) and endothelial markers including sera intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule (VCAM), and matrix metallopeptidase 9 (MMP-9). The secondary outcome was dietary intake, anthropometric indices, serum insulin and Homeostatic Model Assessment of Insulin Resistance (HOMA-IR), total antioxidant capacity (TAC), tumor necrosis factor (TNF), high-sensitivity C-reactive protein (hs-CRP), malondialdehyde (MDA), and lipid profile.
After 8 weeks, Taurine-supplemented patients had a considerable decrease in serum insulin and HOMA-IR compared to placebo group. However, Taurine supplementation did not improve other metabolic parameters including lipid profiles, glycated hemoglobin, and fasting blood glucose (FBG). There was a significant decline in MDA, TNF, and hs-CRP levels after these eight-week period of Taurine supplementation. In addition, the Taurine group had fewer serum levels of endothelial dysfunction markers than the placebo group.
The evidence from our study revealed that Taurine supplementation significantly reduced insulin and HOMA-IR, as well as oxidative stress, inflammation, and endothelial markers in individuals with T2DM. Trial registration The protocol of the study was recorded in the Iranian Registry of Clinical Trials (IRCT20180712040438N3).
补充牛磺酸作为一种含硫氨基酸，可能通过其抗炎和抗氧化活性减轻和/或缓解糖尿病引起的并发症及内皮功能障碍。我们的目的是研究补充牛磺酸对2型糖尿病（T2DM）患者内皮功能障碍标志物、氧化应激、炎症和血糖控制的影响。
在当前的临床试验中，120例T2DM患者被随机分配，每天服用三次牛磺酸（含1克牛磺酸，n = 60）或安慰剂（n = 60），为期八周。此外，所有患者均采用低热量饮食。主要结局指标为空腹血糖（FBG）和内皮标志物，包括血清细胞间黏附分子1（ICAM-1）、血管细胞黏附分子（VCAM）和基质金属蛋白酶9（MMP-9）。次要结局指标为饮食摄入量、人体测量指标、血清胰岛素和胰岛素抵抗稳态模型评估（HOMA-IR）、总抗氧化能力（TAC）、肿瘤坏死因子（TNF）、高敏C反应蛋白（hs-CRP）、丙二醛（MDA）和血脂谱。
8周后，与安慰剂组相比，补充牛磺酸的患者血清胰岛素和HOMA-IR显著降低。然而，补充牛磺酸并未改善其他代谢参数，包括血脂谱、糖化血红蛋白和空腹血糖（FBG）。在补充牛磺酸八周后，MDA、TNF和hs-CRP水平显著下降。此外，牛磺酸组内皮功能障碍标志物的血清水平低于安慰剂组。
我们研究的证据表明，补充牛磺酸可显著降低T2DM患者的胰岛素和HOMA-IR，以及氧化应激、炎症和内皮标志物。试验注册 该研究方案已在伊朗临床试验注册中心（IRCT20180712040438N3）登记。
